All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

October 19th 2023

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Luminary Awards Highlight Exemplary Work of Experts in GI Cancers

October 18th 2023

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have announced the winners of the 2023 Luminary Award in GI cancers.

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC

October 18th 2023

The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.

Data Continue to Support Triplet Therapy With ADT, AR-Targeted Therapy, and Chemotherapy in mHSPC

October 18th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.

Evolving Use of PARP Inhibitors Requires Biomarker-Driven Approaches for Treatment Selection in Prostate Cancer

October 18th 2023

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023

October 18th 2023

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.

ColoAlert’s Novel mRNA Biomarkers Demonstrate Sensitivity, Specificity in Detecting CRC, Advanced Adenoma

October 18th 2023

The novel mRNA biomarkers in the noninvasive ColoAlert® screening test displayed sensitivity and specificity for detecting colorectal cancer and advanced adenomas that could be precursors to CRC.

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18th 2023

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management

October 18th 2023

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

October 17th 2023

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies.

De-Escalation of Therapy Remains a Focus for Early-Stage HER2+ Breast Cancer

October 17th 2023

Francisco Javier Esteva, MD, PhD, discusses the management of early-stage HER2-positive breast cancer with a focus on de-escalation strategies, emphasizes the ongoing efforts to de-escalate chemotherapy without compromising effective treatments, and expands on the ongoing debate regarding the role of carboplatin in this setting.

Experience Helps Guide ILD Prevention/Management With Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 17th 2023

Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.

HPV Discovery Yields Breakthrough in Understanding Protein Activity

October 17th 2023

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

EU Panel Recommends Rucaparib for Frontline Maintenance in Advanced Ovarian Cancer

October 17th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the approval of a Type II variation application for rucaparib as a frontline maintenance in patients with advanced ovarian cancer who have responded to first-line, platinum-based chemotherapy, irrespective of BRCA mutational status.

EMA Grants Orphan Drug Designation to LSTA1 for Pancreatic Cancer

October 17th 2023

The European Medicines Agency’s Committee for Orphan Medical Products has granted orphan drug designation to LSTA1 for the treatment of patients with pancreatic cancer.

Trastuzumab Deruxtecan Continues to Reshape HER2+ Breast Cancer Treatment Paradigm

October 17th 2023

Lubna Chaudhary, MD, MS, discusses how findings from the various DESTINY-Breast trials affected the treatment landscape in HER2-positive breast cancer, the trials’ impact on the treatment arena, the evolving treatment landscape for patients with HER2-positive breast cancer, and the importance of staying updated on new drugs and clinical trials.

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17th 2023

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC

October 16th 2023

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Neoadjuvant Daromun Elicits RFS Benefit in Locally Advanced, Fully Resectable Melanoma

October 16th 2023

Neoadjuvant treatment with intratumoral daromun led to a statistically significant and clinically meaningful improvement in recurrence-free survival compared with surgery alone in patients with locally advanced, fully resectable melanoma, meeting the primary end point of the phase 3 PIVOTAL trial.

Dendritic Cell Vaccination Fails to Improve OS, Still Bolsters Immune Activation in Mesothelioma

October 16th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.